What is the controversy with Repatha?
•
4 min read
In January 2023, a reanalysis published in the journal *BMJ Open* reignited debate over the cardiovascular outcomes data of Repatha (evolocumab). This study, based on a review of the original clinical report, highlights significant inconsistencies, adding another layer to the long-standing question of **what is the controversy with Repatha**.
